- Home
- VLYPO vs VCEL Comparison
VLYPO vs VCEL Comparison
Compare VLYPO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLYPO
- VCEL
- Stock Information
- Founded
- VLYPO N/A
- VCEL 1989
- Country
- VLYPO United States
- VCEL United States
- Employees
- VLYPO 3732
- VCEL N/A
- Industry
- VLYPO Major Banks
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VLYPO Finance
- VCEL Health Care
- Exchange
- VLYPO Nasdaq
- VCEL Nasdaq
- Market Cap
- VLYPO N/A
- VCEL 2.1B
- IPO Year
- VLYPO N/A
- VCEL 1997
- Fundamental
- Price
- VLYPO $24.97
- VCEL $40.25
- Analyst Decision
- VLYPO
- VCEL Strong Buy
- Analyst Count
- VLYPO 0
- VCEL 8
- Target Price
- VLYPO N/A
- VCEL $62.00
- AVG Volume (30 Days)
- VLYPO N/A
- VCEL 477.0K
- Earning Date
- VLYPO N/A
- VCEL 07-31-2025
- Dividend Yield
- VLYPO N/A
- VCEL N/A
- EPS Growth
- VLYPO N/A
- VCEL 521.85
- EPS
- VLYPO N/A
- VCEL 0.05
- Revenue
- VLYPO N/A
- VCEL $238,541,000.00
- Revenue This Year
- VLYPO N/A
- VCEL $23.03
- Revenue Next Year
- VLYPO N/A
- VCEL $24.52
- P/E Ratio
- VLYPO N/A
- VCEL $780.58
- Revenue Growth
- VLYPO N/A
- VCEL 14.80
- 52 Week Low
- VLYPO N/A
- VCEL $37.39
- 52 Week High
- VLYPO N/A
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- VLYPO 55.22
- VCEL 44.06
- Support Level
- VLYPO $24.69
- VCEL $39.39
- Resistance Level
- VLYPO $25.00
- VCEL $42.61
- Average True Range (ATR)
- VLYPO 0.17
- VCEL 1.73
- MACD
- VLYPO 0.03
- VCEL -0.15
- Stochastic Oscillator
- VLYPO 94.16
- VCEL 24.16
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.